A comparison of the long-term effects of lanthanum carbonate and calcium carbonate on the course of chronic renal failure in rats with adriamycin-induced nephropathy.
Lanthanum carbonate (LA) is an effective phosphate binder. Previous study showed the phosphate-binding potency of LA was twice that of calcium carbonate (CA). No study in which LA and CA were given at an equivalent phosphate-binding potency to rats or humans with chronic renal failure for a long period has been reported to date. The objective of this study was to compare the phosphate level in serum and urine and suppression of renal deterioration during long-term LA and CA treatment when they were given at an equivalent phosphate-binding potency in rats with adriamycin (ADR)-induced nephropathy. Rats were divided into three groups: an untreated group (ADR group), a CA-treated (ADR-CA) group and a LA-treated (ADR-LA) group. The daily oral dose of LA was 1.0 g/kg/day and CA was 2.0 g/kg/day for 24 weeks. The serum phosphate was lower in the ADR-CA or ADR-LA group than in the ADR group and significantly lower in the ADR-CA group than in the ADR group at each point, but there were no significant differences between the ADR and ADR-LA groups. The serum phosphate was also lower in the ADR-CA group than in the ADR-LA group, and there was significant difference at week 8. The urinary phosphate was significantly lower in the ADR-CA group than in the ADR or ADR-LA group at each point. The urinary phosphate was also lower in the ADR-LA group than in the ADR group at each point, and significant difference at week 8. There were no significant differences in the serum creatinine or blood urea nitrogen among the three groups. In conclusion, this study indicated the phosphate-binding potency of LA isn't twice as strong as CA, and neither LA nor CA suppressed the progression of chronic renal failure in the serum creatinine and blood urea nitrogen, compared to the untreated group.
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Tsuyoshi
T
Takashima
Department of Nephrology, Fukumitsu Hospital, Fukuoka, Japan.
Toru
T
Sanai
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Motoaki
M
Miyazono
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Makoto
M
Fukuda
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Tomoya
T
Kishi
Department of Nephrology, Ureshino Medical Center, Ureshino, Japan.
Yasunori
Y
Nonaka
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Mai
M
Yoshizaki
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Sae
S
Sato
Department of Nephrology, Faculty of Medicine, Saga University, Saga, Japan.
Yuji
Y
Ikeda
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects; D005966:Glucuronidase / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D007677:Kidney Function Tests; D000090265:Klotho Proteins; D007811:Lanthanum / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D051381:Rats; D013997:Time Factors
C119467:lanthanum carbonate; D007811:Lanthanum; D004317:Doxorubicin; D005966:Glucuronidase; D000090265:Klotho Proteins; D002119:Calcium Carbonate